Business
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear Hospital, Melbourne\n- Preliminary signals of clinical activity observed in the primary uvea, including tumor shrinkage following neoadjuvant darovasertib monotherapy treatment\n- (Neo)adjuvant UM represents an unmet medical need and potential clinical expansion opportunity with annual incidence of approximately 8,700 patients in the US and EU\n- Clinical proof-of-concept data for use in (neo)adjuvant UM setting will be presented with the interim darovasertib Phase 2 clinical data update in MUM in September 2022\nSOUTH SAN FRANCISCO, Calif., Sept. 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent's Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients. \n\n \n \n \n \n \n \n\n \nThe study, captioned as \"Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma\" (NADOM), is being led by principal investigator Professor Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital in Sydney with participating sites of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne. Pursuant to the protocol, the NADOM study will evaluate darovasertib as monotherapy in eligible adult patients having ocular melanoma to determine the feasibility and tolerability of (neo)adjuvant treatment. \n\"We are excited to be leading this ground-breaking clinical study treating patients with darovasertib in the neo-adjuvant and adjuvant settings. The concept for this study originated from anecdotal observations in a MUM patient treated with darovasertib who also had an intact primary lesion in the eye, where a reduction in the eye lesion was observed at an initial scan with improvement in visual symptoms,\" said Professor Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital Sydney. \n\"We are observing an early sign...